Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at Atb Cap Markets reduced their FY2026 EPS estimates for shares of Bradmer Pharmaceuticals in a research report issued on Wednesday, April 23rd. Atb Cap Markets analyst M. Toner now expects that the company will post earnings per share of $0.71 for the year, down from their previous estimate of $0.73.
Several other brokerages have also recently commented on GLX. Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th. BTIG Research upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 14th. Finally, Benchmark upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st.
Bradmer Pharmaceuticals Price Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Calculate Stock Profit
- Short Sellers Gave Up on These 3 Names Recently
- 3 Tickers Leading a Meme Stock Revival
- 3 Boring Stocks Outperforming the Market This Year
- Stock Average Calculator
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
